Clinical Trial Update: AMG 319 in HPV Positive and Negative HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial of AMG 319 in HPV-positive and HPV-negative head and neck squamous cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• AMG 319

Snippet

Sponsor: Cancer Research UK | Conditions: Human Papillomavirus (HPV), Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx, Oropharynx, Oral Cavity, Supraglottis or Larynx | Phase 2 | Status: TERMINATED